Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
https://www.preprints.org/manuscript/202208.0151/v1
Study focuses on cardiovascular effects,
particularly myocarditis and pericarditis events,
after BNT162b2 mRNA COVID-19 vaccine injection,
in Thai adolescents, 13 to 18, both sexes
This prospective cohort study,
students from two schools aged 13–18 years,
who received the second dose of the BNT162b2 vaccine.
All healthy and without any abnormal symptoms before receiving the second dose of vaccine.
Data collected
Demographics
Symptoms
Vital signs
ECG, echocardiography
Cardiac enzymes
Collected
at baseline, Day 3, Day 7, and Day 14
N = 314
Analysis, n = 301
Cardiovascular effects
Found in 29.24% of patients,
ranging from tachycardia, palpitation, and myopericarditis.
Most common cardiovascular effects
Tachycardia, 7.64%
Shortness of breath, 6.64%
Palpitation, 4.32%
Chest pain, 4.32%
Hypertension, 3.99%
Abnormal ECG finding, 54 patients (17.94%)
Seven participants (2.33%)
(all male)
At least one elevated cardiac biomarker or positive lab assessments
Myopericarditis
Confirmed in one patient after vaccination.
Two patients had suspected pericarditis
Four patients had suspected subclinical myocarditis
Three patients had minimal pericardial effusion
Myocarditis and Sudden Cardiac Death in the Young
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.693085
Myocarditis accounts for up to 20% of sudden cardiac deaths in young adults.
During the follow-up period, (14 days)
After receiving the second dose of vaccine,
two patients were hospitalized,
one patient was supervised in the ICU during hospitalization,
(mainly for observation of arrhythmia).
Conclusion
The clinical presentation of myopericarditis after vaccination was usually mild, with all cases fully recovering within 14 days.
Hence, adolescents receiving mRNA vaccines should be monitored for side effects.
Clinical Trial Registration: NCT05288231
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review
https://www.bmj.com/content/378/bmj-2021-069445
Male adolescents and male young adults are at the highest risk of myocarditis after an mRNA vaccination.
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html
Vaccines for COVID-19
COVID-19 vaccines are safe, effective, and free.
COVID-19 Vaccines for Children and Teens
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html
CDC recommends covid -19 vaccines for everyone 6 months and older and boosters for everyone 5 years and older,
https://www.preprints.org/manuscript/202208.0151/v1
Study focuses on cardiovascular effects,
particularly myocarditis and pericarditis events,
after BNT162b2 mRNA COVID-19 vaccine injection,
in Thai adolescents, 13 to 18, both sexes
This prospective cohort study,
students from two schools aged 13–18 years,
who received the second dose of the BNT162b2 vaccine.
All healthy and without any abnormal symptoms before receiving the second dose of vaccine.
Data collected
Demographics
Symptoms
Vital signs
ECG, echocardiography
Cardiac enzymes
Collected
at baseline, Day 3, Day 7, and Day 14
N = 314
Analysis, n = 301
Cardiovascular effects
Found in 29.24% of patients,
ranging from tachycardia, palpitation, and myopericarditis.
Most common cardiovascular effects
Tachycardia, 7.64%
Shortness of breath, 6.64%
Palpitation, 4.32%
Chest pain, 4.32%
Hypertension, 3.99%
Abnormal ECG finding, 54 patients (17.94%)
Seven participants (2.33%)
(all male)
At least one elevated cardiac biomarker or positive lab assessments
Myopericarditis
Confirmed in one patient after vaccination.
Two patients had suspected pericarditis
Four patients had suspected subclinical myocarditis
Three patients had minimal pericardial effusion
Myocarditis and Sudden Cardiac Death in the Young
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.693085
Myocarditis accounts for up to 20% of sudden cardiac deaths in young adults.
During the follow-up period, (14 days)
After receiving the second dose of vaccine,
two patients were hospitalized,
one patient was supervised in the ICU during hospitalization,
(mainly for observation of arrhythmia).
Conclusion
The clinical presentation of myopericarditis after vaccination was usually mild, with all cases fully recovering within 14 days.
Hence, adolescents receiving mRNA vaccines should be monitored for side effects.
Clinical Trial Registration: NCT05288231
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review
https://www.bmj.com/content/378/bmj-2021-069445
Male adolescents and male young adults are at the highest risk of myocarditis after an mRNA vaccination.
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html
Vaccines for COVID-19
COVID-19 vaccines are safe, effective, and free.
COVID-19 Vaccines for Children and Teens
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html
CDC recommends covid -19 vaccines for everyone 6 months and older and boosters for everyone 5 years and older,
